Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cheryl Kyinn

Physician Assistant, Medical San Diego, CA Physician Assistant

NPI 1649570284 CMS profile 11051754

6645 Alvarado Rd, Suite 415, San Diego, CA 92120

Open in the dashboard

General payments

$102,595

1,310 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cheryl Kyinn of San Diego, CA is reported in the CMS Open Payments database as having received $102,595 across 1,310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,814 336
2024 General $31,701 329
2023 General $14,460 248
2022 General $8,141 217
2021 General $5,480 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheryl Kyinn
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Cheryl Kyinn were reported at $42,814. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Cheryl Kyinn Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $5,480 $156 $41–$563 $132
2022 $8,141 $185 $55–$649 $149
2023 $14,460 $199 $58–$717 $160
2024 $31,701 $206 $62–$740 $164
2025 $42,814 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ACADIA Pharmaceuticals Inc $50,422 249 payments
  2. AbbVie, Inc. $24,870 315 payments
  3. Amneal Pharmaceuticals LLC $8,344 90 payments
  4. Teva Pharmaceuticals USA, Inc. $2,875 143 payments
  5. US WorldMeds, LLC $2,284 66 payments
  6. Boston Scientific Corporation $1,445 24 payments
  7. Mitsubishi Tanabe Pharma America, Inc. $1,320 2 payments
  8. Neurocrine Biosciences, Inc. $1,319 51 payments
  9. Adamas Pharmaceuticals, Inc. $1,236 10 payments
  10. Medtronic, Inc. $997 30 payments
  11. Other $7,483 330 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,371 40 payments
  2. Food and Beverage $29,373 1,177 payments
  3. Consulting Fee $17,877 26 payments
  4. Travel and Lodging $10,820 57 payments
  5. Honoraria $815 1 payment
  6. Education $338 9 payments
Products named General payments · program years 2021–2025
  1. NUPLAZID $49,474 226 payments
  2. DUOPA $9,272 76 payments
  3. VYALEV $9,179 42 payments
  4. RYTARY $5,115 55 payments
  5. CREXONT $2,389 34 payments
  6. UBRELVY $2,112 93 payments
  7. Austedo XR $1,754 92 payments
  8. QULIPTA $1,407 63 payments
  9. BOTOX $1,354 76 payments
  10. INGREZZA $1,279 49 payments
  11. Other $14,394 606 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,766

Median for Physician Assistant: 241

Drug cost

$2,010,368

Median for Physician Assistant: $4,110

Branded share of claims

59%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 147 $786,101
Ingrezza Valbenazine Tosylate Brand 12 $169,951
Austedo Xr Deutetrabenazine Brand 28 $167,189
Gocovri Amantadine Hcl Brand 53 $157,355
Rytary Carbidopa/Levodopa Brand 204 $154,332
Nourianz Istradefylline Brand 41 $131,648
Ongentys Opicapone Brand 88 $100,366
Inbrija Levodopa Brand 16 $73,039
Neupro Rotigotine Brand 40 $64,138
Rasagiline Mesylate Generic 170 $40,351

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
$20,762 147 —
RYTARY
$4,407 204 —
Austedo XR
$930 28 —
DUOPA
$597 — —
BOTOX
$535 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record